Audit: QRS - Choline for Health & Longevity

Audit conducted on 17/10/2026 07:25 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	87
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All QRS claims, values, labels and magnitudes trace to ER passages (Conclusion, Therapeutic Protocol, Practical Considerations, Key Interactions & Contraindications, Monitoring table).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious ER phrasing kept: “(theoretical)” on interactions, “(caution; observational)” on contraindications, “(conflicted)” flags, “heart concerns remain unresolved”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No ER claim strengthened or softened.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Facts appear under the same decision categories as in the ER.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	Only FibroScan appears as a brand name; it is in the ER Monitoring table for the same fact. No PMIDs, NCT IDs or expert names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are glossed (cholinesterase inhibitors, anticholinergic drugs, trimethylaminuria, ALT, eGFR, TMAO).
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At a Glance separates adequacy from high-dose supplementation, matching the ER Conclusion.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” wording.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial route or adverse-event terms (“intravenous feeding”, “dose”).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers match the template.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template spans are present; marker_# and qualitative_item_# expanded to 1-5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Spans not addressed in a checklist item (website spans) are unchanged per diff against the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	ER empty tiers (High benefits, High and Speculative risks) are handled by hidden spans per 12.5/13.5; no other source section is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Adequacy target (food-first approach)”, “Gap-filling supplement”, “Targeted cognitive approach”), interaction labels and marker names use the ER bold labels / table labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect labels are derived from the ER “Time to effect” bullet; no paraphrased ER labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji indicators.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Content is condensed per section; no multi-page extension.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	duration is quoted because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	26.10.15 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	2026-1017-0658
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢
5.9	The nickname of the AI is the full name without the version number, with all remaining words joined by hyphens (e.g., Opus, Sonnet, Grok, Gemini-Flash, GPT)	🟢	Opus
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢
5.11	The full name of the AI consists of the model name (the word or words directly before the version number, leaving out the first if there is more than one, e.g., Claude Opus 5.5 → Opus 5.5), the model version number and the variant (if any) as stated in the system prompt or developer instructions of the creating model, with every word capitalized and without product, effort or pricing names (e.g., Opus X.Y, Sonnet X.Y, Grok X.Y, Gemini X.Y Flash, GPT X.Y)	🟢	Opus 5.5
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Choline for Health & Longevity - Quick Reference Sheet”
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	10/17/2026 from 2026-1017-0658.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with “Choline, an essential nutrient … sold as a dietary supplement, helps build cell membranes, export fat from the liver and support memory”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER “Populations who should avoid Choline” items present.
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationales (e.g., “who have an increased risk of fishy body odor”, trial-threshold note) stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	eGFR threshold, age 50+, long-term, “caution; observational” and incidence-not-survival qualifiers preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated; ER names populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine ER interactions with a severity class present; the folate/B12/betaine “No interaction” item correctly omitted.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists, “over-the-counter” and “(theoretical)” preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	ER uses no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated; ER names interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	Section not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides more than three actionable aspects.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The three ER time-to-effect points (3 weeks, 4 weeks, 12 weeks) are used.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Liver items (Medium, non-conflicted) precede memory (Medium, conflicted).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	ER provides three time-to-effect aspects.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are ER heading names; “(conflicted)” / “not central” carry the ER heading flags, not body qualifiers.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No effect sizes, sample notes or study details.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high hidden with display: none and an HTML comment.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high and risks_speculative hidden with display: none.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All five ER table biomarkers listed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers listed verbatim.

Issues 17/10/2026 07:25

Pass rate 100.00%. No issues found.

Issues 17/10/2026 07:22

1. 2.7 — Clinical term “repletion” used: The jargon word “repletion” appears in time_1_label “Liver repletion” (line 483), time_1_sub (line 489) and marker_1_why (line 609) where plain wording such as “restored intake” is available.

Fixes 17/10/2026 07:22

1. 2.7 — Replaced jargon “repletion”: Changed time_1_label “Liver repletion” to “Liver recovery on restored intake”, time_1_sub “of repletion” to “of restoring choline”, and marker_1_why “falls with repletion” to “falls when intake is restored”.

Issues 17/10/2026 07:18

1. 2.7 — Unexplained contraindication jargon: The first Contraindication (QRS line 542) reads “Trimethylaminuria (FMO3 deficiency)”, glossing a disease name only with an enzyme abbreviation; the ER supplies a plain-language meaning (“an inherited inability to clear fishy-smelling trimethylamine”) that the QRS omits.

Fixes 17/10/2026 07:18

1. 2.7 — Plain-language contraindication gloss: Changed “Trimethylaminuria (FMO3 deficiency)” to “Trimethylaminuria (inherited inability to clear fishy-smelling trimethylamine; FMO3 deficiency)”, using the ER’s own wording.

Issues 17/10/2026 07:15

1. 2.7 / 4.2 / 4.3 — Interaction labels abbreviated, jargon: The Key Interactions labels for cholinesterase inhibitors and anticholinergic drugs (QRS lines 554-555) drop the ER’s plain-language descriptors (“dementia drugs that slow acetylcholine breakdown”, “drugs that block acetylcholine”), and “galantamine-containing memory-support blends” is shortened to “galantamine-containing blends” (line 561), so labels are not the ER bold labels verbatim.
2. 4.2 / 4.3 / 9.5 — Antihistamine qualifier dropped: The first-generation antihistamines item (QRS line 558) omits the ER parenthetical qualifier “over-the-counter” (ER line 316).

Fixes 17/10/2026 07:15

1. 2.7 / 4.2 / 4.3 — Interaction labels restored verbatim: Restored the ER descriptors in the Key Interactions labels: “Cholinesterase inhibitors (dementia drugs that slow acetylcholine breakdown; …)”, “Anticholinergic drugs (drugs that block acetylcholine; …)”, and “galantamine-containing blends” changed back to “galantamine-containing memory-support blends”.
2. 4.2 / 4.3 / 9.5 — Antihistamine qualifier restored: Added the ER qualifier “over-the-counter” to the first-generation antihistamines item: “(diphenhydramine, doxylamine; over-the-counter)”.

Issues 17/10/2026 07:11

1. 1.1 — “Lethal” dropped from prostate signal: Contraindications item 5 (QRS line 546) says “prostate-cancer incidence, not survival”, while the ER (line 329) ties the caution to the lethal prostate-cancer signal, so the QRS claim is broader than the ER supports.
2. 9.5 — Aspirin parenthetical qualifier dropped: “Low-dose aspirin: Monitor” (QRS line 557) omits the ER’s whole parenthetical “(over-the-counter)” (ER line 315), which may be shortened but never dropped entirely.

Fixes 17/10/2026 07:11

1. 1.1 — Restored “lethal” prostate qualifier: Changed Contraindications item 5 parenthetical from “prostate-cancer incidence, not survival” to “lethal prostate-cancer incidence, not survival”, matching the ER.
2. 9.5 — Restored aspirin parenthetical qualifier: Changed “Low-dose aspirin: Monitor” to “Low-dose aspirin (over-the-counter): Monitor”, preserving the ER bullet’s parenthetical.

Issues 17/10/2026 07:07

1. 7.2 — Missing execution-oriented bottom line: The At-a-Glance (QRS line 433) omits the Conclusion’s bottom line that “the evidence supports adequacy far more than high-dose supplementation” (ER line 441) and ends on descriptive findings only.

Fixes 17/10/2026 07:07

1. 7.2 — Added execution-oriented bottom line: Replaced “supplement benefit is unproven, and heart concerns remain unresolved.” in the At-a-Glance with “heart concerns remain unresolved. Evidence supports adequacy far more than high-dose supplementation.” (70 words).

Issues 17/10/2026 07:03

1. 2.7 — TMAO and dangling qualifier unexplained: “TMAO” appears at lines 461, 562 and 636 with no plain-language gloss anywhere on the sheet, and the gate item at line 546 ends “incidence, not survival” without naming what it refers to (prostate cancer).

Fixes 17/10/2026 07:03

1. 2.7 — TMAO glossed, qualifier anchored: Changed action_2_sub from “phosphatidylcholine avoids the TMAO surge” to “phosphatidylcholine avoids the surge in TMAO, a heart-risk-linked compound gut microbes make from choline” (ER Recommended Reading wording), and changed the men’s gate qualifier from “incidence, not survival” to “prostate-cancer incidence, not survival”.

Issues 17/10/2026 07:01

1. 1.1 / 1.3 — Supplement claim narrowed: Line 433 at_a_glance says “high-dose supplement benefit is unproven”, while the ER states “supplement benefit is unproven”, softening the ER claim and adding wording not in the ER.
2. 4.2 / 4.3 — Protocol label abbreviated: Line 444 action_1_label reads “Adequacy target (food-first)” instead of the ER bold label “Adequacy target (food-first approach)”.

Fixes 17/10/2026 07:01

1. 1.1 / 1.3 — Supplement claim restored: Changed at_a_glance “high-dose supplement benefit is unproven” to the ER wording “supplement benefit is unproven”.
2. 4.2 / 4.3 — Protocol label restored: Changed action_1_label from “Adequacy target (food-first)” to the ER bold label “Adequacy target (food-first approach)”.